Ralf Gold Selected Research

Daclizumab (Zenapax)

10/2020	Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
10/2017	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
12/2016	Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.
9/2016	Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.
7/2016	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
6/2013	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ralf Gold Research Topics

Disease

163	Multiple Sclerosis 03/2022 - 03/2002
52	Relapsing-Remitting Multiple Sclerosis 01/2022 - 12/2003
50	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2021 - 06/2002
29	Progressive Multifocal Leukoencephalopathy 01/2021 - 12/2008
18	Neuroinflammatory Diseases 01/2022 - 06/2002
18	Inflammation (Inflammations) 01/2022 - 10/2002
18	Demyelinating Diseases (Demyelinating Disease) 01/2021 - 06/2002
16	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 05/2022 - 04/2003
16	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 08/2002
15	Infections 01/2021 - 12/2008
13	Neuromyelitis Optica (Devic's Disease) 01/2022 - 03/2013
12	Experimental Autoimmune Neuritis 01/2021 - 08/2002
11	Polyneuropathies (Polyneuropathy) 05/2022 - 09/2006
11	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2013
10	Chronic Progressive Multiple Sclerosis 09/2022 - 09/2007
10	Disease Progression 03/2022 - 12/2008
9	Atrophy 01/2022 - 12/2013
9	Immune Reconstitution Inflammatory Syndrome 01/2021 - 11/2010
8	Neoplasms (Cancer) 06/2020 - 04/2004
8	Myasthenia Gravis 01/2019 - 03/2005
8	Thymoma (Thymic Carcinoma) 09/2015 - 04/2004
8	Guillain-Barre Syndrome 05/2014 - 08/2002
7	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 03/2008
7	Huntington Disease (Huntington's Disease) 01/2018 - 04/2010
6	Neuritis (Polyneuritis) 03/2019 - 09/2014
5	Pain (Aches) 01/2022 - 07/2015
5	Birth Weight (Birth Weights) 01/2020 - 05/2009
4	COVID-19 07/2022 - 01/2021
4	Stroke (Strokes) 12/2021 - 01/2015
4	Opportunistic Infections (Opportunistic Infection) 01/2021 - 01/2014
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 01/2012
4	Stiff-Person Syndrome (Stiff Man Syndrome) 12/2016 - 04/2005
4	Flushing 09/2015 - 10/2008
3	Lymphopenia (Lymphocytopenia) 11/2021 - 01/2018
3	Optic Neuritis (Retrobulbar Neuritis) 05/2021 - 07/2015
3	Central Nervous System Diseases (CNS Diseases) 02/2020 - 06/2002
3	Chronic Disease (Chronic Diseases) 01/2020 - 10/2009
3	Seizures (Absence Seizure) 12/2019 - 01/2011
3	Neurocognitive Disorders (Clerambault Syndrome) 01/2019 - 11/2014
3	Cognitive Dysfunction 01/2019 - 11/2010
3	Herpes Zoster 01/2018 - 07/2015
3	Hypersensitivity (Allergy) 07/2017 - 09/2007

Drug/Important Bio-Agent (IBA)

42	Natalizumab (Tysabri)FDA Link 01/2022 - 09/2007
41	Dimethyl FumarateIBA 01/2022 - 10/2008
19	Myelin-Oligodendrocyte GlycoproteinIBA 01/2022 - 06/2002
17	AntibodiesIBA 10/2020 - 03/2005
16	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2009
16	Intravenous Immunoglobulins (IVIG)FDA Link 12/2021 - 10/2002
13	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2002
13	FumaratesIBA 01/2021 - 03/2008
13	CytokinesIBA 01/2021 - 06/2002
12	Rituximab (Mabthera)FDA Link 01/2022 - 05/2008
11	Immunoglobulin G (IgG)IBA 01/2022 - 04/2005
11	Monoclonal AntibodiesIBA 01/2020 - 07/2003
11	Interferon-betaIBA 01/2016 - 04/2003
10	Neuroprotective AgentsIBA 01/2022 - 08/2010
9	AutoantibodiesIBA 01/2022 - 04/2005
9	Pharmaceutical PreparationsIBA 01/2021 - 11/2010
9	Fingolimod Hydrochloride (FTY720)FDA Link 08/2019 - 05/2013
8	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 03/2008
8	Peptides (Polypeptides)IBA 01/2021 - 08/2002
8	laquinimodIBA 06/2018 - 03/2011
8	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2015 - 05/2002
7	siponimodIBA 09/2022 - 01/2018
7	teriflunomideIBA 10/2020 - 04/2014
7	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2019 - 01/2009
6	GlucocorticoidsIBA 01/2021 - 11/2006
6	Daclizumab (Zenapax)FDA Link 10/2020 - 06/2013
6	Glatiramer Acetate (Copaxone)FDA Link 11/2016 - 05/2006
5	IronIBA 01/2021 - 01/2016
5	Bortezomib (Velcade)FDA Link 01/2021 - 10/2016
5	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021 - 11/2003
5	SteroidsIBA 03/2019 - 09/2007
5	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019 - 01/2009
5	Cholinergic ReceptorsIBA 01/2019 - 03/2005
5	N-acetyltalosaminuronic acid (NAT)IBA 07/2017 - 05/2013
4	Prednisolone (Predate)FDA LinkGeneric 01/2021 - 08/2003
4	AntigensIBA 01/2019 - 10/2002
4	InterferonsIBA 08/2017 - 12/2003
4	Levetiracetam (Keppra)FDA LinkGeneric 09/2016 - 01/2011
4	Ciliary Neurotrophic Factor (CNTF)IBA 02/2008 - 03/2002
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2003 - 04/2002
3	Sphingosine-1-Phosphate ReceptorsIBA 09/2022 - 01/2017
3	EnzymesIBA 01/2022 - 07/2016
3	propionic acid (potassium propionate)IBA 01/2022 - 01/2020
3	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2022 - 03/2013
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 12/2008
3	Biological ProductsIBA 01/2021 - 01/2009
3	Therapeutic UsesIBA 06/2020 - 10/2011
3	ocrelizumabIBA 01/2020 - 01/2019
3	Alemtuzumab (Campath)FDA Link 01/2019 - 01/2017
3	daclizumab HYPIBA 01/2018 - 06/2013
3	Interferon beta-1a FDA Link 10/2017 - 01/2012
3	Hormones (Hormone)IBA 07/2017 - 08/2003

Therapy/Procedure

103	Therapeutics 03/2022 - 10/2002
12	Immunotherapy 03/2022 - 08/2002
7	Plasma Exchange 07/2016 - 04/2003
4	Drug Therapy (Chemotherapy) 05/2022 - 09/2008
4	Plasmapheresis 01/2021 - 04/2005
3	Immunomodulation 01/2017 - 04/2010